Search results for "Oral administration"

showing 10 items of 165 documents

Lipid Nanoparticles as Potential Gene Therapeutic Delivery Systems for Oral Administration.

2017

Background Gene therapy has experimented an increasing attention in the last decades, due to its enormous potential applications in the medical field. It can be defined as the use of genes or genetic material (DNA, RNA, oligonucleotides) to treat or prevent a disease state, generally a geneticbased one. Application Other applications, like treating viral, bacterial or parasite infections or development of vaccines are gaining also interest. Efficient gene therapy is mainly dependent on the ability of the highly labile genetic material to reach the therapeutic target. For this purpose, different delivery systems have been designed and extensively investigated. Nanoparticles offer a broad ran…

0106 biological sciences0301 basic medicineGenetic enhancementAdministration OralComputational biologyBiologyGene deliveryPharmacology01 natural sciences03 medical and health sciencesDrug Delivery SystemsOral administration010608 biotechnologyNucleic AcidsDrug DiscoverySolid lipid nanoparticleGeneticsOral routeAnimalsHumansParasite InfectionsMolecular BiologyGeneGenetics (clinical)Drug CarriersGene Transfer TechniquesGenetic TherapyBiocompatible materialLipids030104 developmental biologyMolecular MedicineNanoparticlesCurrent gene therapy
researchProduct

Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model

2017

The therapy of inflammatory bowel diseases is still rather inefficient, and about 80% of patients require surgery at some stage. Improving the treatments by more efficient medication is, therefore, an urgent medical need. The objective of this project was to demonstrate targeted delivery of Cyclosporine-A (CYA) to the inflamed areas of the intestinal mucosa after oral administration, enabling improved alleviation of the symptoms and, at the same time, reduced systemic drug absorption and associated adverse effects. As had already been demonstrated in previous studies, nano- to micrometer-sized drug particles will accumulate at inflamed mucosal areas, providing a platform for such purposes. …

0301 basic medicineDrugColonPolymersmedia_common.quotation_subjectAdministration OralBiological AvailabilityPharmaceutical Science02 engineering and technologyPharmacologyInflammatory bowel diseaseMice03 medical and health sciencesDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerIntestinal mucosaOral administrationAnimalsMedicineLactic AcidIntestinal MucosaParticle SizeAdverse effectmedia_commonDrug CarriersMice Inbred BALB CCrohn's diseasebusiness.industryGeneral MedicineInflammatory Bowel Diseases021001 nanoscience & nanotechnologymedicine.diseaseBioavailabilityDisease Models Animal030104 developmental biologyCyclosporineNanoparticlesNanocarriers0210 nano-technologybusinessPolyglycolic AcidBiotechnologyEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Oral Monosodium Glutamate Administration Causes Early Onset of Alzheimer's Disease-Like Pathophysiology in APP/PS1 Mice.

2019

Glutamate excitotoxicity has long been related to Alzheimer's disease (AD) pathophysiology, and it has been shown to affect the major AD-related hallmarks, amyloid-β peptide (Aβ) accumulation and tau phosphorylation (p-tau). We investigated whether oral administration of monosodium glutamate (MSG) has effects in a murine model of AD, the double transgenic mice APP/PS1. We found that AD pathogenic factors appear earlier in APP/PS1 when supplemented with MSG, while wildtype mice were essentially not affected. Aβ and p-tau levels were increased in the hippocampus in young APP/PS1 animals upon MSG administration. This was correlated with increased Cdk5-p25 levels. Furthermore, in these mice, we…

0301 basic medicineGenetically modified mouseMalemedicine.medical_specialtyMonosodium glutamateExcitotoxicityHippocampusAdministration OralMice TransgenicAMPA receptormedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundAmyloid beta-Protein PrecursorMice0302 clinical medicineOral administrationAlzheimer DiseaseInternal medicinemental disordersSodium GlutamatemedicinePresenilin-1Animalsbusiness.industryGeneral NeuroscienceGlutamate receptorLong-term potentiationGeneral MedicineFlavoring AgentsPsychiatry and Mental healthClinical Psychology030104 developmental biologyEndocrinologychemistryFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryJournal of Alzheimer's disease : JAD
researchProduct

Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models

2020

International audience; Mucopolysaccharidoses are a class of lysosomal storage diseases, characterized by enzymatic deficiency in the degradation of specific glycosaminoglycans (GAG). Pathological accumulation of excess GAG leads to multiple clinical symptoms with systemic character, most severely affecting bones, muscles and connective tissues. Current therapies include periodic intravenous infusion of supplementary recombinant enzyme (Enzyme Replacement Therapy-ERT) or bone marrow transplantation. However, ERT has limited efficacy due to poor penetration in some organs and tissues. Here, we investigated the potential of the β-D-xyloside derivative odiparcil as an oral GAG clearance therap…

0301 basic medicineMaleMucopolysaccharidosis type VIRespiratory SystemAdministration OralGlycosaminoglycanRats Sprague-DawleyWhite Blood CellsMice0302 clinical medicineOral administrationAnimal CellsMedicine and Health SciencesGlycosidesCells CulturedConnective Tissue CellsGlycosaminoglycansMultidisciplinaryMucopolysaccharidosis VIChemistryChondroitin SulfatesQRMucopolysaccharidosis VIAnimal Models3. Good healthTracheamedicine.anatomical_structureExperimental Organism SystemsConnective Tissue[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyMedicineFemaleBiological CulturesCellular TypesAnatomyCellular Structures and OrganellesResearch Articlemedicine.medical_specialtyImmune CellsScienceImmunologyDermatan SulfateMouse ModelsIn Vitro TechniquesResearch and Analysis Methods03 medical and health sciencesModel OrganismsIn vivoInternal medicinemedicineAnimalsHumansBlood CellsCartilageBiology and Life SciencesEndothelial CellsKidneysCell BiologyRenal SystemFibroblastsCell CulturesIn vitroMice Mutant StrainsRatsMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinologyBiological TissueCartilageCell cultureAnimal Studies[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyCattleLysosomes030217 neurology & neurosurgery
researchProduct

The metabolism of mono-(2-ethylhexyl) phthalate (MEHP) and liver peroxisome proliferation in the hamster.

1988

This study has investigated the in vivo metabolism of mono-(2-ethylhexyl) phthalate (MEHP), the initial metabolite of di-(2-ethylhexyl) phthalate in mammals, and the hepatic peroxisome proliferation induced by this compound following multiple oral administration to hamsters. Hamsters received [14C]-MEHP, by gavage, at doses of 50 and 500 mg/kg body wt on each of three consecutive days. Urine was collected every 24 hours and metabolite profiles were determined using capillary gas-chromatography. Multiple high doses of MEHP (500 mg/kg) induced a change in the relative proportions of metabolites produced. As previously reported for the rat, metabolites derived from sequential ω-following by β…

0301 basic medicineMalemedicine.medical_specialtyHealth Toxicology and MutagenesisMetabolitePhthalic AcidsHamsterPeroxisome Proliferation010501 environmental sciencesToxicology01 natural sciencesMicrobodies03 medical and health scienceschemistry.chemical_compoundOral administrationInternal medicineCricetinaeDiethylhexyl PhthalatemedicineAnimals0105 earth and related environmental sciences030102 biochemistry & molecular biologyPublic Health Environmental and Occupational HealthPhthalateMetabolismPeroxisomeRatsEndocrinologychemistryLiverGlucuronideOxidation-ReductionToxicology and industrial health
researchProduct

Signature of Circulating Biomarkers in Recurrent Non-Infectious Anterior Uveitis. Immunomodulatory Effects of DHA-Triglyceride. A Pilot Study

2021

The purpose of this study was to identify circulating biomarkers of recurrent non-infectious anterior uveitis (NIAU), and to address the anti-inflammatory effects of triglyceride containing docosahexaenoic acid (DHA-TG). A prospective multicenter study was conducted in 72 participants distributed into: patients diagnosed with recurrent NIAU in the quiescence stage (uveitis group (UG)

0301 basic medicineMedicine (General)medicine.medical_specialtyClinical BiochemistryÀcids grassos omega-3GastroenterologyArticlerecurrent anterior non-infectious uveitisUveitis03 medical and health scienceschemistry.chemical_compoundR5-9200302 clinical medicineOral administrationInternal medicineOmega-3 fatty acidsMedicineTriglicèridsStage (cooking)Triglyceridesomega-3 fatty acidsTriglyceridebusiness.industryInterleukintriglyceride of docosahexaenoic acidmedicine.diseasecytokinesCirculating biomarkers030104 developmental biologychemistryDocosahexaenoic acidUveïtis030221 ophthalmology & optometryTumor necrosis factor alphabusinessUveitisDiagnostics
researchProduct

Milk and blood biomarkers associated to the clinical efficacy of a probiotic for the treatment of infectious mastitis

2016

Previous studies have shown the efficacy of oral administration of selected lactobacilli strains to treat mastitis. The objective of this study was to find microbiological, biochemical and/or immunological biomarkers of the probiotic effect. Women with (n=23) and without (n=8) symptoms of mastitis received three daily doses (109 cfu) of Lactobacillus salivarius PS2 for 21 days. Samples of milk, blood and urine were collected before and after the probiotic intervention, and screened for a wide spectrum of microbiological, biochemical and immunological parameters. In the mastitis group, L. salivarius PS2 intake led to a reduction in milk bacterial counts, milk and blood leukocyte counts and i…

0301 basic medicineMicrobiology (medical)UrinalysisAdministration OralMastitisUrineUrinalysisMicrobiologylaw.invention03 medical and health sciencesProbioticOral administrationlawHumansMedicineMilk Humanbiologymedicine.diagnostic_testbusiness.industryProbioticsLactobacillus salivariusfood and beveragesInterleukinbiology.organism_classificationmedicine.diseaseLactobacillus salivariusMastitisTreatment OutcomeBloodMilk030104 developmental biologyImmunologyLigilactobacillus salivariusbiology.proteinFemaleAntibodybusinessBiomarkersBlood Chemical AnalysisBeneficial Microbes
researchProduct

Oral administration of Bifidobacterium bifidum G9-1 alleviates rotavirus gastroenteritis through regulation of intestinal homeostasis by inducing muc…

2017

Human rotavirus (RV) infection is a leading cause of dehydrating diarrhea in infants and young children worldwide. Since therapeutic approaches to RV gastroenteritis are limited to alleviation of dehydration with oral rehydration solutions, more direct approaches to palliate symptoms of RV gastroenteritis are required. Treatments with probiotics have been increasingly recognized as alternative safe and low cost treatments for moderate infectious diarrhea. In this study, Bifidobacterium bifidum G9-1 (BBG9-1), which has been used as an intestinal drug for several decades, was shown to have a remarkable protective effect against RV gastroenteritis in a suckling mice model. As well as prophylac…

0301 basic medicineRotavirusMalabsorptionved/biology.organism_classification_rank.speciesAdministration Orallcsh:MedicinePathology and Laboratory MedicineBiochemistryCecumOral administrationChlorocebus aethiopsMedicine and Health SciencesLarge intestinelcsh:ScienceCecumGastrointestinal tractMice Inbred BALB CMultidisciplinaryGastroenteritisIntestinesDiarrheamedicine.anatomical_structureJejunumSmall Intestinemedicine.symptomAnatomyResearch ArticleDiarrheaGastroenterology and HepatologyRotavirus InfectionsCell Line03 medical and health sciencesSigns and SymptomsDiagnostic MedicineIleummedicineAnimalsBifidobacterium bifidumved/biologybusiness.industryProbioticslcsh:RBiology and Life SciencesProteinsmedicine.diseaseMacaca mulattaSmall intestineGastrointestinal Tract030104 developmental biologyGene Expression RegulationImmunologyMucinlcsh:QBifidobacterium bifidumbusinessDigestive SystemPLoS ONE
researchProduct

Localized Interleukin-12 for Cancer Immunotherapy

2020

Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable antitumor efficacy in preclinical models has yet to be replicated in humans. Early clinical trials in the mid-1990's showed that systemic delivery of IL-12 incurred dose-limiting toxicities. Nevertheless, IL-12's pleiotropic activity, i.e., its ability to engage multiple effector mechanisms and reverse tumor-induced immunosuppression, continues to entice cancer researchers. The development of strategies which maximize IL-12 delivery to the tumor microenvironment while minimizing systemic exposure are of increasing interest…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_treatmentDrug CompoundingImmunologyGenetic Vectorsinterleukin-12 (IL-12)Antineoplastic AgentsReviewBioinformatics03 medical and health sciences0302 clinical medicineCancer immunotherapyNeoplasmsintratumoral administrationTumor MicroenvironmentImmunology and AllergyMedicineAnimalsHumansTumor microenvironmentDrug Carrierscancer immunotherapyAntitumor immunitybusiness.industryGene Transfer TechniquesCancerImmunotherapyGenetic Therapymedicine.diseaseInterleukin-12Clinical trialcytokine delivery system030104 developmental biologyTreatment OutcomeInterleukin 12Cancer vaccineImmunotherapybusinesslcsh:RC581-607cancer vaccinelocalized delivery030215 immunologyFrontiers in Immunology
researchProduct

Chiral Serum Pharmacokinetics of 4-Fluoroamphetamine after Controlled Oral Administration

2021

Abstract Over the last two decades, misuse of 4-fluoroamphetamine (4-FA) became an emerging issue in many European countries. Stimulating effects last for 4–6 hours and can impact psychomotor performance. The metabolism of amphetamine-type stimulants is stereoselective and quantification of (R)- and (S)-enantiomers has been suggested for assessing time of use. To date, no data on enantioselective pharmacokinetics is available for 4-FA in serum samples. An enantioselective liquid chromatography−tandem mass spectrometry (LC–MS-MS) method was developed using a chiral Phenomenex® Lux 3 μm AMP column. Validation of the method showed satisfactory selectivity, sensitivity, linearity (0.5–250 ng/mL…

3SAMPLESHealth Toxicology and MutagenesisNETHERLANDSAdministration OralAMPHETAMINEMETABOLISMMETHAMPHETAMINEToxicology01 natural sciencesSTEREOSELECTIVE PHARMACOKINETICSAnalytical Chemistry03 medical and health sciences4-Fluoroamphetamine0302 clinical medicinePharmacokineticsTandem Mass SpectrometryOral administrationmedicineHumansEnvironmental ChemistryIngestion030216 legal & forensic medicineChemical Health and SafetyChromatography34-METHYLENEDIOXYMETHAMPHETAMINEChemistryAmphetamines010401 analytical chemistryTRANSPORTERStereoisomerism4-METHYLENEDIOXYMETHAMPHETAMINESerum samples0104 chemical sciencesStereoselectivityFLUOROAMPHETAMINEEnantiomerPSYCHOACTIVE SUBSTANCES NPSTime of useChromatography Liquidmedicine.drugJournal of Analytical Toxicology
researchProduct